Myasthenia Gravis Market to See Strong Growth Through 2035 – BIS Research

What Is Myasthenia Gravis? 

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder that weakens skeletal muscles, impairing voluntary movements such as breathing, swallowing, and limb coordination. The condition arises due to the immune system targeting acetylcholine receptors at the neuromuscular junction. Standard treatment includes cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, plasmapheresis, and IVIg therapies. 

What Is the Market Outlook? 

Therapeutic Innovation: Continuous development of monoclonal antibodies, novel biologics, and improved corticosteroid formulations is expanding therapeutic options. 

Diagnostic Advancements: Progress in antibody-based assays, electromyography, and imaging tools is improving early detection and patient stratification. 

Healthcare Access: Growth is fueled by rising healthcare spending in developed regions and improving infrastructure in emerging economies. 

Strategic Partnerships: Leading pharmaceutical firms are investing heavily in R&D, collaborations, and licensing agreements to strengthen their competitive edge. 

How Fast Is the Market Growing? 

The global myasthenia gravis market is expected to record a steady CAGR between 2025 and 2035. Growth is reinforced by increasing awareness, expanding insurance coverage, and the commercialization of innovative biologics. Demand is strong in North America and Europe, while Asia-Pacific is emerging as a fast-growing region due to healthcare infrastructure upgrades and increasing disease recognition. 

How Will This Report Help You? 

Planning to Enter the Market? 

Identify opportunities in monoclonal antibodies, IVIg therapies, and next-generation autoimmune treatments. 

Analyzing the Competitive Landscape? 

Evaluate the strategies of global leaders such as Argenx SE, UCB Pharma, Johnson & Johnson, and AstraZeneca. 

Seeking R&D Insights? 

Track pipeline developments in biologics, small molecules, and diagnostic tools enhancing precision medicine. 

Interested in Regional Market Trends? 

Assess adoption rates, regulatory pathways, and government initiatives shaping growth across major geographies. 

Download the Full TOC or Book a Preview 

What Technologies Are Transforming the Market? 

• Monoclonal Antibody Therapies 
• Next-Generation Immunotherapies 
• Intravenous Immunoglobulin (IVIg) Advancements 
• Plasma Exchange (Plasmapheresis) Systems 
• Diagnostic Innovations (Antibody Testing, EMG) 

What’s Driving Demand, Opportunities, and Barriers? 

Demand Drivers 

• Rising incidence of autoimmune and neuromuscular disorders 
• Growing aging population with higher MG prevalence 
• Increasing availability of advanced biologics and diagnostics 

Opportunities 

• Expansion of biologics and targeted therapies 
• Rising investments in emerging healthcare markets 
• Integration of MG treatment into broader autoimmune disease management platforms 

Challenges

• High cost of biologics and advanced therapies 
• Limited treatment access in low- and middle-income countries 
• Need for skilled professionals for diagnosis and treatment delivery 

Market Segmentation 

By Drug Type: 

• Cholinesterase Inhibitors 
• Monoclonal Antibodies 
• Corticosteroids 
• Others 

By Region: 

• North America 
• Europe 
• Asia-Pacific 
• Rest-of-the-World 

Key Players 

• Argenx SE 
• UCB Pharma 
• Johnson & Johnson 
• AstraZeneca 
• Novartis AG 
• Roivant Sciences 
• NMD Pharma A/S 
• Bausch Health Companies Inc. 
• Amgen Inc. 
• Teva Pharmaceutical Industries Ltd. 
• Merck & Co., Inc. 

Strategic Developments 

• Expansion of clinical trials for biologics and monoclonal antibodies 
• Partnerships and licensing agreements to broaden therapeutic portfolios 
• Increasing adoption of plasma exchange and IVIg therapies in clinical practice 

Download the complete TOC now! 

Case Study 

The report highlights clinical adoption of biologics such as efgartigimod (by Argenx SE), which demonstrated significant improvement in MG patient outcomes during pivotal trials. Case studies also showcase the effectiveness of IVIg and plasmapheresis in managing acute MG exacerbations, underscoring how rapid interventions can reduce hospitalization time, improve quality of life, and enhance long-term patient management. 

Schedule a Call with Industry Experts  

Related Reports from BIS Research  

Hepatic Encephalopathy Market 

Fuchs Endothelial Corneal Dystrophy Market 

Familial Chylomicronemia Syndrome Market 

About BIS Research  

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.    

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.     

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.    

Contact  

Head of Marketing   

Email: media@bisresearch.com     

BIS Research Inc.    

39111 PASEO PADRE PKWY STE 313,    

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights    

Get Expert Insights @https://community.insightmonk.com     

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research     

Connect with us on Twitter@ https://twitter.com/BISResearch    

Connect with us on Medium@ https://medium.com/@faisal.bis  

Connect with us on YouTube@ https://www.youtube.com/@BISResearchInc